BBI:NSD-Brickell Biotech, Inc

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.51

Change

-0.01 (-0.22)%

Market Cap

USD 0.04B

Volume

0.03M

Average Target Price

N/A
Average Analyst Rating

N/A

STA Verdict

Verdict

About

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead products candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. The company was founded in 2009 and is based in Boulder, Colorado.

Market Stats

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-09-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+2.61 (+1.49%)

USD 44.97B 20.53 41.60
REGN Regeneron Pharmaceuticals, Inc

+4.27 (+1.52%)

USD 30.93B 15.64 12.43
ALXN Alexion Pharmaceuticals, Inc

+1.14 (+1.06%)

USD 24.08B 18.20 10.98
INCY Incyte Corporation

+1.91 (+2.50%)

USD 16.44B 53.79 40.58
BMRN BioMarin Pharmaceutical Inc

+1.56 (+2.15%)

USD 13.04B N/A -203.31
GMAB Genmab A/S

+0.04 (+0.20%)

USD 12.96B N/A -0.00
SGEN Seattle Genetics, Inc

+0.48 (+0.68%)

USD 11.42B N/A -54.28
GLPG Galapagos NV

-2.76 (-1.71%)

USD 9.94B 72.40 0.00
ALNY Alnylam Pharmaceuticals, Inc

+1.08 (+1.29%)

USD 9.31B N/A -8.80
IONS Ionis Pharmaceuticals, Inc

-1.07 (-1.62%)

USD 9.30B 23.32 72.05

ETFs Containing BBI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.04B 19% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 8.90 7% F 40% F
EV/EBITDA -6.56 74% C 86% B
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 13.93% 85% B 82% B-
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.37 94% A 91% A-
Short Percent 1.19% 87% B+ 76% C
Beta -0.13 92% A- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector